Arrowstreet Capital’s First Tracks Biotherapeutics TRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding TRAX
Arrowstreet Capital's TRAX Position: Q3 2026 in Review
Arrowstreet Capital sold out of First Tracks Biotherapeutics (TRAX) in Q3 2026, closing a stake of 299,500 shares — an estimated $6.03M sold.
Arrowstreet Capital first reported a position in TRAX in Q2 2026 and held it in 1 quarter. The position peaked at $6.03M in Q2 2026. 174 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.
- Arrowstreet Capital reported no remaining First Tracks Biotherapeutics position as of Q3 2026 after selling out during the quarter.
- Arrowstreet Capital sold 299,500 First Tracks Biotherapeutics shares in Q3 2026, an estimated $6.03M.
- Arrowstreet Capital first reported a position in First Tracks Biotherapeutics in Q2 2026 and held it in 1 quarter.
- Arrowstreet Capital's First Tracks Biotherapeutics position peaked at $6.03M in Q2 2026.
- 174 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.
Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.